activity
20242026
most citedA Survey of Generative AI for de novo Drug Design: New Frontiers in Molecule and Protein Generation

4 citations · 8 across the 12 of their papers we have counts for

collaborators

13 papers

cs.AI2026

AgentFold: Closed-Loop Agentic Search for Protein Folding Model Design

Mingquan Liu, Jiangyu Chen, Hanqun Cao +9

Scientific LLM agents have shown promise in literature reasoning, tool use, and experiment planning, but it remains unclear whether they can autonomously improve large, tightly cou…

cs.AI2026

Capturing LLM Capabilities via Evidence-Calibrated Query Clustering

Fangzhou Wu, Sandeep Silwal, Qiuyi Zhang

Query clustering organizes queries into groups that reflect shared latent capability demands, enabling capability-aware LLM evaluation. Existing clustering methods, which primarily…

cs.LG2026

DynMuon: A Dynamic Spectral Shaping View of Muon

Fangzhou Wu, Rikhav Shah, Sandeep Silwal +1

In recent years, Muon has emerged as the dominant method for training large language models, and transformers more broadly. The essential difference, when compared to standard grad…

q-bio.BM2026

SurfDesign: Effective Protein Design on Molecular Surfaces

Fang Wu, Shuting Jin, Xiangru Tang +5

Protein function is largely determined by molecular surface geometry and physicochemical complementarity, yet most protein design methods condition only on backbone structure. We i…

cs.CE2026

GeoCycler: Reward-Aligned 3D Diffusion for Constraint-Conditioned Cyclic Peptide Design

Jingjie Zhang, Hanqun Cao, Haosen Shi +10

Cyclic peptides are attractive therapeutic modalities because their closed-ring topology can improve stability and target specificity. However, de novo cyclic peptide design remain…

cs.AI2026

Latent Action Reparameterization for Efficient Agent Inference

Wenhao Huang, Qingwen Zeng, Qiyue Chen +11

Large language model (LLM) agents often rely on long sequences of low-level textual actions, resulting in large effective decision horizons and high inference cost. While prior wor…

cs.LG2026

Hypergraph Pattern Machine: Compositional Tokenization for Higher-Order Interactions

Kyrie Zhao, Zehong Wang, Tianyi Ma +5

Hypergraphs model higher-order relations that drive real-world decisions, from drug prescriptions to recommendations. A central structural signal in such data, beyond what pairwise…

cs.LG2026

Proteo-R1: Reasoning Foundation Models for De Novo Protein Design

Fang Wu, Weihao Xuan, Heli Qi +26

Deep learning in de novo protein design has achieved atomic-level fidelity. However, existing models remain largely non-deliberative: they directly synthesize molecular geometries…

cs.LG2025★ 3 cited

AI Scientists for Building Virtual-Cell Models

Xiangru Tang, Zhuoyun Yu, Jiapeng Chen +12

Autonomous agents, from virtual laboratories to biological data-analysis agents and co-scientists, have begun to turn scientific goals into hypotheses. Whether they can go further…

cs.CL2025

Agent KB: Leveraging Cross-Domain Experience for Agentic Problem Solving

Xiangru Tang, Tianrui Qin, Tianhao Peng +15

AI agent frameworks operate in isolation, forcing agents to rediscover solutions and repeat mistakes across different systems. Despite valuable problem-solving experiences accumula…

cs.CL2025

MedicalAgentsBench for Complex Medical Reasoning: Comparing Internalized Reasoning Models versus Externalized Agent-based Frameworks

Yanjun Shao, Xiangru Tang, Jiwoong Sohn +10

Complex medical reasoning requires integrating heterogeneous clinical evidence across multiple inference steps. Large language models (LLMs) now approach this through two routes: i…

cs.CE2024★ 1 cited

D-Flow: Multi-modality Flow Matching for D-peptide Design

Fang Wu, Shuting Jin, Xiangru Tang +3

Among these, D-peptides are resistant to proteolysis, exhibit greater in vivo stability, and are easier to synthesize. Despite advances in deep learning for peptide discovery, the…

q-bio.BM2024★ 4 cited

A Survey of Generative AI for de novo Drug Design: New Frontiers in Molecule and Protein Generation

Xiangru Tang, Howard Dai, Elizabeth Knight +4

Artificial intelligence (AI)-driven methods can vastly improve the historically costly drug design process, with various generative models already in widespread use. Generative mod…